A Phase 1A/B Dose Escalation Study Of The Mutation Agnostic Flt3/Btk Inhibitor Luxeptinib (Cg-806) In Patients With Relapsed Or Refractory Acute Myeloid Leukemia
CG-806
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: A Phase 1A/B Dose Escalation Study Of The Mutation Agnostic Flt3/Btk Inhibitor Luxeptinib (Cg-806) In Patients With Relapsed Or Refractory Acute Myeloid Leukemia ### Output: CG-806